Menu
Search
|

Menu

Close
X

Galapagos NV GLPG.AS (Amsterdam Stock Exchange)

91.12 EUR
-- (--)
As of Nov 14
chart
Previous Close 91.12
Open --
Volume --
3m Avg Volume 446,356
Today’s High --
Today’s Low --
52 Week High 105.35
52 Week Low 70.64
Shares Outstanding (mil) 54.43
Market Capitalization (mil) 5,015.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 12 analysts

KEY STATS

Revenue (mm, EUR)
FY18
205
FY17
156
FY16
186
FY15
61
EPS (EUR)
FY18
-0.882
FY17
-2.315
FY16
1.040
FY15
-3.214
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
19.70
22.95
Price to Book (MRQ)
vs sector
4.21
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
0.00
15.47
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-6.19
13.00
Return on Equity (TTM)
vs sector
-6.66
14.69

EXECUTIVE LEADERSHIP

Onno van de Stolpe
Chairman of the Executive Committee, Chief Executive Officer, Executive Director, Since 1999
Salary: €394,543.00
Bonus: --
Rajesh Parekh
Non-Executive Chairman of the Board, Since 2004
Salary: --
Bonus: --
Bart Filius
Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Piet Wigerinck
Member of the Executive Committee, Chief Scientific Officer, Since 2012
Salary: --
Bonus: --
Walid Abi-Saab
Member of the Executive Committee, Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Generaal De Wittelaan 3
MALINES (MECHELEN)     2800

Phone: +3215.342900
Site: www.glpg.com

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

SPONSORED STORIES